ABCSG 42/PALLAS Summary

PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Start: 08/2015; national: 10/2015
Coordinating investigator: Gnant, Michael; Vienna
Sample size: 5.600 (international)
Design:
(Click to enlarge)
ABCSG 42/PALLAS

Please note that the protocol amendment may not be locally approved at your participating site/in your participating country yet. Please only implement/execute the updated protocol upon issuance of full local EC/regulatory approval.

Dataprotection

Information for study participants in studies sponsored by ABCSG/ABCSG GmbH